The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific.
MRI-detected signs of cardiac remodeling may tell clinicians a thing or two about a patient's odds of developing certain cancers. Changes in heart muscle mass, for example, were linked to an increased risk of breast cancer.
A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients?
Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.
